About: Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
Creator	Alard, Emilie Butnariu, Aura-Bianca Grillo, Marta Kirkham, Charlotte Macciochi, Jenna Newnham, Louise Pranjol, Islam Zahidul, Md Zinovkin, Dmitry
source	Medline; PMC
abstract	Unlike traditional cancer therapies, such as surgery, radiation and chemotherapy that are typically non-specific, cancer immunotherapy harnesses the high specificity of a patient’s own immune system to selectively kill cancer cells. The immune system is the body’s main cancer surveillance system, but cancers may evade destruction thanks to various immune-suppressing mechanisms. We therefore need to deploy various immunotherapy-based strategies to help bolster the anti-tumour immune responses. These include engineering T cells to express chimeric antigen receptors (CARs) to specifically recognise tumour neoantigens, inactivating immune checkpoints, oncolytic viruses and dendritic cell (DC) vaccines, which have all shown clinical benefit in certain cancers. However, treatment efficacy remains poor due to drug-induced adverse events and immunosuppressive tendencies of the tumour microenvironment. Recent preclinical studies have unveiled novel therapies such as anti-cathepsin antibodies, galectin-1 blockade and anti-OX40 agonistic antibodies, which may be utilised as adjuvant therapies to modulate the tumour microenvironment and permit more ferocious anti-tumour immune response.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.3390/cancers12071826
bibo:pmid	32645977
has license	cc-by
sha1sum (hex)	907eb4d0edcdb899e3d3bfb63ba2ddc64b1411ce
schema:url	https://doi.org/10.3390/cancers12071826
resource representing a document's title	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
has PubMed Central identifier	PMC7408985
has PubMed identifier	32645977
schema:publication	Cancers (Basel)
resource representing a document's body	covid:907eb4d0edcdb899e3d3bfb63ba2ddc64b1411ce#body_text
is schema:about of	named entity 'POOR' named entity 'THESE' named entity 'CANCER CELLS' named entity 'CANCER IMMUNOTHERAPY' named entity 'IMMUNE SYSTEM' named entity 'vaccines' named entity 'chemotherapy' named entity 'cancer therapies' named entity 'dendritic cell' named entity 'antibodies' named entity 'Checkpoint Inhibitors' named entity 'Dendritic Cell' named entity 'CD28' named entity 'TME' named entity 'survival rate' named entity 'immunogenic' named entity 'castration resistant' named entity 'immune responses' named entity 'PD-1 and PD-L1' named entity 'anti-tumour' named entity 'solid cancer' named entity 'clinical trial' named entity 'OX40' named entity 'sorafenib' named entity 'TNBC' named entity 'extracellular matrix proteins' named entity 'DCs' named entity 'immune responses' named entity 'melanoma' named entity 'antitumor' named entity 'haematological cancers' named entity 'aspartic acid' named entity 'agonists' named entity 'EGFRvIII' named entity 'viruses' named entity 'ipilimumab' named entity 'LAG-3' named entity 'PD-L1' named entity 'lung tissue' named entity 'tumour' named entity 'cancer cells' named entity 'MHC II' named entity 'PD-L1' named entity 'breast cancer' named entity 'chemotherapy' named entity 'fallopian tube' named entity 'cancer treatment' named entity 'PD-1' named entity 'respiratory tract' named entity 'genetic engineering' named entity 'retroviral vector' named entity 'phase I clinical trial' named entity 'advanced stages' named entity 'antigen' named entity 'follow-up' named entity 'anti-PD-1' named entity 'co-expression' named entity 'response rate' named entity 'CAR T cell' named entity 'CD4+ T cells' named entity 'natural killer (NK) cells' named entity 'PD-1' named entity 'metastases' named entity '13.8' named entity 'immunosuppressive' named entity 'radiation therapy' named entity 'animal studies' named entity 'CAR T cells' named entity 'PD-1' named entity 'lysate' named entity 'clinical trials' named entity 'tumour cells' named entity 'prognosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software